

A Substructure Combination Strategy To Create Potent and Selective Transthyretin Kinetic Stabilizers That Prevent Amyloidogenesis and Cytotoxicity

Sungwook Choi,[†] Natàlia Reixach,[‡] Stephen Connelly,[§] Steven M. Johnson,[†] Ian A. Wilson,[§] and Jeffery W. Kelly^{*,†,‡}

Departments of Chemistry, Molecular and Experimental Medicine, and Molecular Biology, and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

Received October 7, 2009; E-mail: jkelly@scripps.edu.

Abstract: Transthyretin aggregation-associated proteotoxicity appears to cause several human amyloid diseases. Rate-limiting tetramer dissociation and monomer misfolding of transthyretin (TTR) occur before its aggregation into cross- β -sheet amyloid fibrils. Small molecule binding to and preferential stabilization of the tetrameric state of TTR over the dissociative transition state raises the kinetic barrier for dissociation, imposing kinetic stabilization on TTR and preventing aggregation. This is an effective strategy to halt neurodegeneration associated with polyneuropathy, according to recent placebo-controlled clinical trial results. In three recent papers, we systematically ranked possibilities for the three substructures composing a typical TTR kinetic stabilizer, using fibril inhibition potency and plasma TTR binding selectivity data. Herein, we have successfully employed a substructure combination strategy to use these data to develop potent and selective TTR kinetic stabilizers that rescue cells from the cytotoxic effects of TTR amyloidogenesis. Of the 92 stilbene and dihydrostilbene analogues synthesized, nearly all potently inhibit TTR fibril formation. Seventeen of these exhibit a binding stoichiometry of >1.5 of a maximum of 2 to plasma TTR, while displaying minimal binding to the thyroid hormone receptor ($<20\%$). Six analogues were definitively categorized as kinetic stabilizers by evaluating dissociation time-courses. High-resolution TTR·(kinetic stabilizer)₂ crystal structures (1.31–1.70 Å) confirmed the anticipated binding orientation of the 3,5-dibromo-4-hydroxyphenyl substructure and revealed a strong preference of the isosteric 3,5-dibromo-4-aminophenyl substructure to bind to the inner thyroxine binding pocket of TTR.

Introduction

Intrinsic and/or extrinsic challenges to the maintenance of organismal protein homeostasis, in the absence of a biological correction (e.g., induction of a stress-responsive signaling pathway) or a chemical correction (a small molecule that binds to and stabilizes a particular misfolding-prone protein) to rebalance the proteostasis network, can lead to aging-associated proteotoxicity and degenerative diseases.^{1–5} These include Alzheimer's disease, as well as the transthyretin and gelsolin amyloidoses.^{3,5–10} These maladies are associated with the accumulation of an insoluble protein(s), including amyloid fibrils

after which these diseases have been named, leading to the degeneration of one or more tissues, often those composed of postmitotic cells, such as neurons or muscle cells.^{3,6,10} Whether intra- or extracellular aggregates lead to degeneration, which aggregate morphology is responsible, and by what mechanism are key unanswered questions related to the amyloidoses.^{3–11}

Transthyretin (TTR) is a homotetrameric protein composed of 127-amino-acid, β -sheet-rich subunits.^{12–15} The established physiological functions of TTR are to bind to and transport the thyroid hormone thyroxine (T₄) and holo-retinol binding protein

[†] Department of Chemistry and The Skaggs Institute for Chemical Biology.

[‡] Department of Molecular and Experimental Medicine.

[§] Department of Molecular Biology and The Skaggs Institute for Chemical Biology.

(1) Balch, W. E.; Morimoto, R. I.; Dillin, A.; Kelly, J. W. *Science* **2008**, *319*, 916–9.

(2) Powers, E. T.; Morimoto, R. I.; Dillin, A.; Kelly, J. W.; Balch, W. E. *Annu. Rev. Biochem.* **2009**, *78*, 959–91.

(3) Cohen, E.; Bieschke, J.; Perciavalle, R. M.; Kelly, J. W.; Dillin, A. *Science* **2006**, *313*, 1604–10.

(4) Sekijima, Y.; Wiseman, R. L.; Matteson, J.; Hammarstrom, P.; Miller, S. R.; Sawkar, A. R.; Balch, W. E.; Kelly, J. W. *Cell* **2005**, *121*, 73–85.

(5) Hammarstrom, P.; Wiseman, R. L.; Powers, E. T.; Kelly, J. W. *Science* **2003**, *299*, 713–6.

(6) Page, L. J.; Suk, J. Y.; Bazhenova, L.; Fleming, S. M.; Wood, M.; Jiang, Y.; Guo, L. T.; Mizisin, A. P.; Kisilevsky, R.; Shelton, G. D.; Balch, W. E.; Kelly, J. W. *Proc. Natl. Acad. Sci. U.S.A.* **2009**, *106*, 11125–30.

(7) Coelho, T. *Curr. Opin. Neurol.* **1996**, *9*, 355–9.

(8) Dobson, C. M. *Nature* **2003**, *426*, 884–90.

(9) Cohen, F. E.; Kelly, J. W. *Nature* **2003**, *426*, 905–9.

(10) Selkoe, D. J. *Nature* **2003**, *426*, 900–4.

(11) Johnson, S. M.; Wiseman, R. L.; Sekijima, Y.; Green, N. S.; Adamski-Werner, S. L.; Kelly, J. W. *Acc. Chem. Res.* **2005**, *38*, 911–21.

(12) Monaco, H. L.; Rizzi, M.; Coda, A. *Science* **1995**, *268*, 1039–41.

(13) Blake, C. C.; Geisow, M. J.; Oatley, S. J.; Rerat, B.; Rerat, C. *J. Mol. Biol.* **1978**, *121*, 339–56.

(14) Hornberg, A.; Eneqvist, T.; Olofsson, A.; Lundgren, E.; Sauer-Eriksson, A. E. *J. Mol. Biol.* **2000**, *302*, 649–69.

(15) Sacchettini, J. C.; Kelly, J. W. *Nat. Rev. Drug Discovery* **2002**, *1*, 267–75.

in the blood and cerebrospinal fluid (CSF).^{11,12,16–18} Although TTR serves as the major carrier of thyroxine in the CSF, TTR is a minor carrier in blood because of the presence of two other T₄ carrier proteins, thyroxine binding globulin and albumin. Thus, more than 99% of TTR's T₄ binding sites in the blood are unoccupied.¹¹

Transthyretin is one of more than 30 nonhomologous human amyloidogenic proteins, whose misfolding and/or misassembly appears to elicit the proteotoxicity and cell degeneration thought to cause the amyloidoses.^{4,7,11,19} Amyloidogenesis from TTR secreted by the liver appears to require rate-limiting tetramer dissociation, which affords nonamyloidogenic folded monomers that must undergo partial denaturation to misassemble into a variety of aggregate structures, including cross- β -sheet amyloid fibrils.^{20–25} TTR amyloidogenesis occurs by a thermodynamically favorable or downhill aggregation reaction, and not by a nucleated polymerization that governs many other amyloidogenesis processes.²⁶ Amyloidogenesis could also compete with TTR monomer folding in the endoplasmic reticulum of hepatocytes, although this source of proteotoxicity is still under debate. The demonstrated effectiveness of a kinetic stabilizer in a placebo-controlled clinical trial for polyneuropathy suggests that dissociation of the TTR tetramer is the predominant process that leads to TTR proteotoxicity.⁴ Accumulation of either wild type (WT) TTR or mutant TTR aggregates outside of cells, and possibly later inside certain cells, appears to cause the neurodegeneration and/or organ degeneration characteristic of the TTR amyloidoses.

Amyloidogenesis of WT-TTR within the heart leads to the sporadic amyloid disease, senile systemic amyloidosis (SSA), a late onset cardiomyopathy that affects up to 20% of the aged population.^{27–29} Familial amyloid cardiomyopathy (FAC) appears to be caused by the deposition of one of a few TTR mutants within the heart, the most common variant deposited being V122I-TTR, a mutation found in 3–4% of African Americans that appears to confer complete penetrance of FAC.^{30,31} Both SSA and FAC result from TTR proteotoxicity in trans, as heart tissue does not synthesize TTR.

Amyloidogenesis of one of over 100 thermodynamically less stable variants of TTR^{4,32,33} appears to cause familial amyloid polyneuropathy (FAP), a peripheral neuropathy, often exhibiting autonomic nervous system involvement.³⁴ The most common FAP variant is V30M-TTR, affecting largely the Portuguese, Swedish, and Japanese populations.^{35–37} Central nervous system selective amyloidosis (CNSA) appears to be a rarer disease associated with the deposition of the most destabilized TTR variants (e.g., A25T- and D18G-TTR) in the brain, but not in the periphery.^{4,38,39} The choroid plexus secreting these variants into the CSF appears to be a more permissive secretor of unstable and misfolding-prone TTR variants than the liver, which extensively degrades these highly destabilized variants instead of secreting them into the blood, explaining why the peripheral tissues are not subjected to A25T- and D18G-TTR amyloidogenesis.^{4,38–40}

There are currently no FDA-approved drugs or accepted therapeutic strategies for treating SSA and FAC. The only therapeutic strategy currently being practiced for ameliorating FAP is gene therapy mediated by liver transplantation, wherein the disease-associated TTR variant producing liver is replaced by a WT-TTR producing liver, substantially reducing disease-associated variant TTR levels in the blood.^{41–43} The drawbacks of utilizing liver transplantation to treat FAP include the shortage of livers, the significant surgical risk, life-long immune suppression requirements, and the expense. In addition, WT-TTR continues to deposit in the heart post-transplantation, leading to cardiomyopathy, suggesting an aging-associated decline in the proteostasis capacity of the heart.^{1,2,44–46} Because of the limited applicability of liver transplantation to treat the TTR amyloidoses (not applicable to SSA, the disease with the most patients) and especially the risk of death from transplant complications, it is highly desirable to develop a general chemotherapeutic strategy for ameliorating the TTR amyloidoses.^{11,47,48} Toward this end, we have been developing kinetic stabilizers of TTR, small molecules that differentially stabilize the native tetrameric structure

- (16) White, J. T.; Kelly, J. W. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 13019–24.
- (17) Wojtczak, A.; Luft, J.; Cody, V. *J. Biol. Chem.* **1992**, *267*, 353–7.
- (18) Soprano, D. R.; Herbert, J.; Soprano, K. J.; Schon, E. A.; Goodman, D. S. *J. Biol. Chem.* **1985**, *260*, 1793–8.
- (19) Reixach, N.; Deechongkit, S.; Jiang, X.; Kelly, J. W.; Buxbaum, J. N. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 2817–22.
- (20) Colon, W.; Kelly, J. W. *Biochemistry* **1992**, *31*, 8654–60.
- (21) Lai, Z.; Colon, W.; Kelly, J. W. *Biochemistry* **1996**, *35*, 6470–82.
- (22) Lashuel, H. A.; Lai, Z.; Kelly, J. W. *Biochemistry* **1998**, *37*, 17851–64.
- (23) Liu, K.; Cho, H. S.; Lashuel, H. A.; Kelly, J. W.; Wemmer, D. E. *Nat. Struct. Biol.* **2000**, *7*, 754–7.
- (24) Jiang, X.; Smith, C. S.; Petrassi, H. M.; Hammarstrom, P.; White, J. T.; Sacchettini, J. C.; Kelly, J. W. *Biochemistry* **2001**, *40*, 11442–52.
- (25) Palaninathan, S. K.; Mohamedmohaideen, N. N.; Snee, W. C.; Kelly, J. W.; Sacchettini, J. C. *J. Mol. Biol.* **2008**, *382*, 1157–67.
- (26) Hurshman, A. R.; White, J. T.; Powers, E. T.; Kelly, J. W. *Biochemistry* **2004**, *43*, 7365–81.
- (27) Westermark, P.; Bergstrom, J.; Solomon, A.; Murphy, C.; Sletten, K. *Amyloid* **2003**, *10*, 48–54.
- (28) Westermark, P.; Sletten, K.; Johansson, B.; Cornwell, G. G. *Proc. Natl. Acad. Sci. U.S.A.* **1990**, *87*, 2843–5.
- (29) Buxbaum, J. N.; Tagoe, C. E. *Annu. Rev. Med.* **2000**, *51*, 543–69.
- (30) Jiang, X.; Buxbaum, J. N.; Kelly, J. W. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 14943–8.
- (31) Jacobson, D. R.; Pastore, R. D.; Yaghoubian, R.; Kane, I.; Gallo, G.; Buck, F. S.; Buxbaum, J. N. *N. Engl. J. Med.* **1997**, *336*, 466–73.

- (32) Hammarstrom, P.; Jiang, X.; Hurshman, A. R.; Powers, E. T.; Kelly, J. W. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 16427–32.
- (33) Hurshman, A. R.; Powers, E. T.; Kelly, J. W. *Biochemistry* **2008**, *47*, 6969–84.
- (34) Andrade, C. *Brain* **1952**, *75*, 408–27.
- (35) Plante-Bordeneuve, V.; Said, G. *Curr. Opin. Neurol.* **2000**, *13*, 569–73.
- (36) Coelho, T.; Choroa, R.; Sausa, A.; Alves, I.; Torres, M. F.; Saraiva, M. J. *Neuromusc. Disord.* **1996**, *6*, 27.
- (37) Saraiva, M. J. *Amyloid* **2003**, *10*, 13–6.
- (38) Sekijima, Y.; Hammarstrom, P.; Matsumura, M.; Shimizu, Y.; Iwata, M.; Tokuda, T.; Ikeda, S.; Kelly, J. W. *Lab. Invest.* **2003**, *83*, 409–17.
- (39) Hammarstrom, P.; Sekijima, Y.; White, J. T.; Wiseman, R. L.; Lim, A.; Costello, C. E.; Altland, K.; Garzuly, F.; Budka, H.; Kelly, J. W. *Biochemistry* **2003**, *42*, 6656–63.
- (40) Gambetti, P.; Russo, C. *Nephrol. Dial. Transplant* **1998**, *13*, 33–40.
- (41) Holmgren, G.; Ericzon, B. G.; Groth, C. G.; Steen, L.; Suhr, O.; Andersen, O.; Wallin, B. G.; Seymour, A.; Richardson, S.; Hawkins, P. N. *Lancet* **1993**, *341*, 1113–6.
- (42) Tan, S. Y.; Pepys, M. B.; Hawkins, P. N. *Am. J. Kidney Dis.* **1995**, *26*, 267–85.
- (43) Suhr, O. B.; Herlenius, G.; Friman, S.; Ericzon, B. G. *Liver Transplant* **2000**, *6*, 263–76.
- (44) Olofsson, B. O.; Backman, C.; Karp, K.; Suhr, O. B. *Transplantation* **2002**, *73*, 745–51.
- (45) Dubrey, S. W.; Davidoff, R.; Skinner, M.; Bergethon, P.; Lewis, D.; Falk, R. H. *Transplantation* **1997**, *64*, 74–80.
- (46) Yazaki, M.; Tokuda, T.; Nakamura, A.; Higashikata, T.; Koyama, J.; Higuchi, K.; Harihara, Y.; Baba, S.; Kametani, F.; Ikeda, S. *Biochem. Biophys. Res. Commun.* **2000**, *274*, 702–6.
- (47) Tojo, K.; Sekijima, Y.; Kelly, J. W.; Ikeda, S. I. *Neurosci. Res.* **2006**, *56*, 441–9.
- (48) Sekijima, Y.; Dendle, M. A.; Kelly, J. W. *Amyloid* **2006**, *13*, 236–49.

of TTR over the dissociative transition state, making the barrier for TTR tetramer dissociation too high to surmount under physiological conditions, thus preventing TTR amyloidogenesis.^{5,11,49–56} A phase II/III placebo-controlled clinical trial has recently been completed by FoldRx Pharmaceuticals for one of the kinetic stabilizers synthesized by our laboratory, demonstrating that it halts neurodegeneration (www.foldrx.com). The demonstrated utility of a TTR kinetic stabilizer to ameliorate a TTR amyloid disease is further supported by human genetic evidence. The incorporation of T119M-TTR trans-suppressor subunits into TTR heterotetramers otherwise composed of FAP-associated subunits kinetically stabilizes the TTR tetramer and ameliorates FAP amyloidogenesis in Portuguese compound heterozygotes.^{5,36,49}

The energetically weaker dimer–dimer interface of tetrameric TTR,⁵⁴ bisected by the crystallographic C_2 axis (Figure 1A), creates the two funnel-shaped T_4 binding pockets.^{11–14,17,57} To date, we have synthesized over one thousand small molecules that exhibit structural complementarity to the T_4 binding sites within TTR and bind with a range of affinities and cooperativities.^{5,11,15,47,48,52,55–72} We have recently conducted a systematic three-part study to

optimize the three substructures comprising a typical TTR kinetic stabilizer, the two aromatic rings (aryl-X and aryl-Z), and the linker-Y connecting them (Figure 1B).^{58–60} In each paper, we rank-ordered the numerous possibilities for one substructure, based on their ability to inhibit TTR fibril formation and to bind selectively to TTR in human plasma, the remainder of the structure being constant. We also evaluated the highly ranked substructures for their ability to bind to the thyroid hormone receptor or cyclooxygenase.^{58–60} We created a so-called efficacy score, eq 1 (discussed in detail below) integrating TTR amyloid inhibition efficacy data (dependent on the extent of kinetic stabilization of TTR) and plasma TTR binding stoichiometry data into one score.

$$\text{average efficacy score} = \frac{(100\% - \%F.F._{\text{ave}}) \times (1 + P.S._{\text{ave}})}{300\%} \quad (1)$$

While structure-based drug design principles were not employed implicitly in these studies, we were aware that one of the most highly ranked aryl-X substructures strongly prefers to bind in the outer thyroxine binding subsite (Figure 1B, bottom left) for reasons outlined below. In addition, we knew that the *trans* $-\text{CH}=\text{CH}-$ and $-\text{CH}_2-\text{CH}_2-$ linkers maximized the hydrophobic effect upon binding to TTR. Numerous TTR•(kinetic stabilizer)₂ crystal structures reveal the key molecular interactions required for high affinity binding to the two T_4 sites.^{57–60,62–67} Pertinent to this study, aryl-X rings bearing a 4-hydroxyl substituent flanked by bromides strongly prefer to bind in the outer binding subsite, bridging subunits by making salt bridging interactions with the Lys-15/15' ϵ -ammonium groups and by maximizing occupancy of halogen binding pockets (HBPs) 1 and 1'.⁵⁸ Electron-withdrawing substituents at the 3 and 5 positions (e.g., Br, Cl) flanking a 4-hydroxyl group result in phenolate formation (pK_a lowering) at neutral pH.⁵⁸ Benzoxazole, biphenyl, biphenylether, and biphenylamide TTR cocrystal structures all reveal that the 3,5-dibromo-4-hydroxyphenyl substructure comprising them strongly prefers to be placed in the outer binding site to make Lys15 salt bridges.^{59,60} Hence, we expect the 3,5-dibromo-4-hydroxyphenyl ring comprising the stilbenes and dihydrostilbenes used in this study to occupy the outer T_4 binding pocket. Moreover, we expect the *trans* double bond linker and the $-\text{CH}_2-\text{CH}_2-$ linker used in this exercise to interact with the hydrophobic side chains of Leu17/17', Ala108/108', Leu110/110', and Val121/121', maximizing the hydrophobic effect and thus binding affinity, based on crystal structures of WT-TTR•(Resveratrol (1))₂⁵⁷ (Figure 1A and C) and the complexes between WT-TTR and other stilbenes having only one of the two aromatic rings bearing substituents.⁵⁹

On the basis of the data from the substructure optimization studies,^{58–60} we tested the hypothesis that we could produce a small molecule library that is rich in potent and highly selective kinetic stabilizers by simply combining the most highly ranked substructures. We utilized the highly ranked 3,5-dibromo-4-hydroxy-substituted aryl-X ring and isosteric variants thereof (replacing the hydroxyl group with functional groups like NH_2), a variety of highly ranked aryl-Z rings, as well as desirable hydrophobic linkers (*trans* $-\text{CH}=\text{CH}-$ and $-\text{CH}_2-\text{CH}_2-$) to demonstrate that the substructure combination strategy affords a library with a high proportion of potent and highly selective

- (49) Hammarstrom, P.; Schneider, F.; Kelly, J. W. *Science* **2001**, *293*, 2459–62.
- (50) Lai, Z.; McCulloch, J.; Lashuel, H. A.; Kelly, J. W. *Biochemistry* **1997**, *36*, 10230–9.
- (51) Foss, T. R.; Kelker, M. S.; Wiseman, R. L.; Wilson, I. A.; Kelly, J. W. *J. Mol. Biol.* **2005**, *347*, 841–54.
- (52) Wiseman, R. L.; Johnson, S. M.; Kelker, M. S.; Foss, T.; Wilson, I. A.; Kelly, J. W. *J. Am. Chem. Soc.* **2005**, *127*, 5540–51.
- (53) Wiseman, R. L.; Green, N. S.; Kelly, J. W. *Biochemistry* **2005**, *44*, 9265–74.
- (54) Foss, T. R.; Wiseman, R. L.; Kelly, J. W. *Biochemistry* **2005**, *44*, 15525–33.
- (55) Miroy, G. J.; Lai, Z.; Lashuel, H. A.; Peterson, S. A.; Strang, C.; Kelly, J. W. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, *93*, 15051–6.
- (56) Peterson, S. A.; Klabunde, T.; Lashuel, H. A.; Purkey, H.; Sacchettini, J. C.; Kelly, J. W. *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *95*, 12956–60.
- (57) Klabunde, T.; Petrassi, H. M.; Oza, V. B.; Raman, P.; Kelly, J. W.; Sacchettini, J. C. *Nat. Struct. Biol.* **2000**, *7*, 312–21.
- (58) Johnson, S. M.; Connelly, S.; Wilson, I. A.; Kelly, J. W. *J. Med. Chem.* **2008**, *51*, 260–70.
- (59) Johnson, S. M.; Connelly, S.; Wilson, I. A.; Kelly, J. W. *J. Med. Chem.* **2008**, *51*, 6348–58.
- (60) Johnson, S. M.; Connelly, S.; Wilson, I. A.; Kelly, J. W. *J. Med. Chem.* **2009**, *52*, 1115–25.
- (61) Petrassi, H. M.; Johnson, S. M.; Purkey, H.; Chiang, K. P.; Walkup, T.; Jiang, X.; Powers, E. T.; Kelly, J. W. *J. Am. Chem. Soc.* **2005**, *127*, 6662–71.
- (62) Razavi, H.; Palaninathan, S. K.; Powers, E. T.; Wiseman, R. L.; Purkey, H. E.; Mohamedmohaideen, N. N.; Deechongkit, S.; Chiang, K. P.; Dendle, M. T.; Sacchettini, J. C.; Kelly, J. W. *Angew. Chem., Int. Ed.* **2003**, *42*, 2758–61.
- (63) Purkey, H. E.; Palaninathan, S. K.; Kent, K. C.; Smith, C.; Safe, S. H.; Sacchettini, J. C.; Kelly, J. W. *Chem. Biol.* **2004**, *11*, 1719–28.
- (64) Oza, V. B.; Smith, C.; Raman, P.; Koepf, E. K.; Lashuel, H. A.; Petrassi, H. M.; Chiang, K. P.; Powers, E. T.; Sacchettini, J.; Kelly, J. W. *J. Med. Chem.* **2002**, *45*, 321–32.
- (65) Adamski-Werner, S. L.; Palaninathan, S. K.; Sacchettini, J. C.; Kelly, J. W. *J. Med. Chem.* **2004**, *47*, 355–74.
- (66) Petrassi, H. M.; Klabunde, T.; Sacchettini, J. C.; Kelly, J. W. *J. Am. Chem. Soc.* **2000**, *122*, 2178–92.
- (67) Johnson, S. M.; Petrassi, H. M.; Palaninathan, S. K.; Mohamedmohaideen, N. N.; Purkey, H.; Nichols, C.; Chiang, K. P.; Walkup, T.; Sacchettini, J. C.; Sharpless, K. B.; Kelly, J. W. *J. Med. Chem.* **2005**, *48*, 1756–87.
- (68) Wojtczak, A.; Cody, V.; Luft, J. R.; Pangborn, W. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **1996**, *52*, 758–65.
- (69) Baures, P. W.; Oza, V. B.; Peterson, S. A.; Kelly, J. W. *Bioorg. Med. Chem.* **1999**, *7*, 1339–47.
- (70) Baures, P. W.; Peterson, S. A.; Kelly, J. W. *Bioorg. Med. Chem.* **1998**, *6*, 1389–401.
- (71) McCammon, M. G.; Scott, D. J.; Keetch, C. A.; Greene, L. H.; Purkey, H. E.; Petrassi, H. M.; Kelly, J. W.; Robinson, C. V. *Structure* **2002**, *10*, 851–63.

- (72) Green, N. S.; Palaninathan, S. K.; Sacchettini, J. C.; Kelly, J. W. *J. Am. Chem. Soc.* **2003**, *125*, 13404–14.





Figure 1. Substructure combination strategy to identify potent and selective TTR kinetic stabilizers. (A) Ribbon diagram depiction of the crystal structure (PDB accession code 1DVS) of resveratrol (**1**) bound to the two thyroxine (T₄) binding pockets within the WT-TTR tetramer, with the monomer subunits individually colored. The top portion represents an expanded view of one T₄ binding site with **1** bound with a “Connelly” analytical molecular surface applied to residues within 8 Å of ligand in the T₄ binding pocket (green = hydrophobic, purple = polar). (B) Schematic depiction of the substructure combination strategy to create TTR kinetic stabilizers (top). The aryl-X and aryl-Z rings as well as the linker-Y can be varied to generate candidate TTR kinetic stabilizers. The most highly ranked aryl-X, aryl-Z, and linker-Y substructures from previous studies, based on potency and plasma TTR binding stoichiometry, are combined in this substructure combination strategy to create potent and selective TTR kinetic stabilizers that nearly eliminate amyloidogenesis associated cytotoxicity. The inner and outer T₄ binding subsites within one schematically represented TTR T₄ binding site are labeled in red font. (C) The innermost halogen binding pockets (HBPs) 3 and 3' (labeled in A) are composed of the methyl and methylene groups of Ser117/117', Thr119/119', and Leu110/110'. HBPs 2 and 2' (labeled in A) are made up of the side chains of Leu110/110', Ala109/109', Lys15/15', and Leu17/17'. The outermost HBPs 1 and 1' (labeled in A) are lined by the methyl and methylene groups of Lys15/15', Ala108/108', and Thr106/106'. This figure was generated using the program MOE (2006.08), Chemical Computing Group, Montreal, Canada.

TTR kinetic stabilizers/amyloidogenesis inhibitors. Structural studies reinforce prior data on the binding preference of the 3,5-dibromo-4-hydroxyphenyl substructure to the outer T₄ binding subsite^{58–60} and, importantly, reveal the strong preference of the 3,5-dibromo-4-aminophenyl substructure to bind to the inner T₄ binding subsite. The ability of all of the TTR kinetic stabilizers tested in this study to nearly eliminate TTR-induced cytotoxicity in the recently developed cell culture assay suggests

that they merit further study as potential drug candidates to ameliorate the human TTR amyloidoses.

Results

Having established previously that a stilbene comprising one 3,5-dibromo-4-hydroxyphenyl ring and one unsubstituted aryl ring exhibits a binding stoichiometry to TTR of 1.5 out of a maximum of 2 in human plasma and completely inhibits TTR



	F 2	Cl 3	Br 4	I 5	CH ₃ 6	CF ₃ 7	CN 8	OCH ₃ 9	OH 10	OCHF ₂ 11	NO ₂ 12	NH ₂ 13	CO ₂ Me 14	CO ₂ H 15	Average Efficacy Score
	1% 1.36 0.78	1% 1.43 0.80	1% 1.51 0.83	1% 1.56 0.85	2% 1.57 0.84	2% 1.66 0.87	5% 1.27 0.72	0% 1.67 0.89	1% 1.68 0.88	0% 1.73 0.91	5% 1.66 0.84	0% 1.56 0.85	1% 1.12 0.70	1% 0.16 0.38	0.80
	1% 1.49 0.82	1% 1.45 0.81	1% 1.37 0.78	1% 1.74 0.90	0% 1.52 0.84	2% 1.45 0.80	2% 1.36 0.78	0% 1.63 0.88	1% 1.70 0.89	1% 1.48 0.82	6% 1.15 0.67	0% 1.76 0.92	2% 1.28 0.75	0% 1.25 0.75	0.82
	1% 1.67 0.88	1% 1.32 0.77	2% 1.22 0.73	5% 1.03 0.64	0% 1.47 0.82	16% 1.47 0.82	7% 0.83 0.57	0% 1.58 0.86	1% 1.75 0.91	5% 1.38 0.76	11% 1.38 0.76	1% 1.93 0.97	13% 1.93 0.97	1% 1.18 0.72	0.76
	1% 1.43 0.80	1% 1.68 0.88	1% 1.55 0.84	0% 1.55 0.85	0% 1.55 0.85	0% 1.55 0.85	0% 1.52 0.84	0% 1.52 0.84	0% 1.52 0.84	0% 1.52 0.84	0% 1.52 0.84	0% 1.52 0.84	0% 1.52 0.84	0% 1.52 0.84	0.84
	2% 1.34 0.76	45% 1.34 0.76	61% 1.34 0.76	0% 1.69 0.90	0% 1.69 0.90	40% 1.69 0.90	1% 1.31 0.76	0% 1.83 0.94	0% 1.83 0.94	0% 1.83 0.94	22% 1.83 0.94	22% 1.83 0.94	22% 1.83 0.94	22% 1.83 0.94	0.67
Average Efficacy Score	0.81	0.74	0.70	0.80	0.85	0.72	0.69	0.85	0.91	0.83	0.72	0.91	0.70	0.62	

Figure 2. Evaluation of the potency and selectivity of stilbene-based TTR kinetic stabilizers. Percent (%) fibril formation (F.F.) values are in black font representing the extent of *in vitro* WT-TTR (3.6 μ M) fibril formation in the presence of inhibitor (7.2 μ M) relative to aggregation in the absence of inhibitor (assigned to be 100%). The TTR tetramer binding stoichiometry of potent aggregation inhibitors (defined as those exhibiting <10% F.F.) bound to human plasma TTR *ex vivo* is shown in blue font (10.8 μ M kinetic stabilizer concentration, maximum binding stoichiometry is 2 due to the two thyroxine binding sites per TTR tetramer). Extent of competitive binding of potent (based on % F.F. as defined above) and highly selective (defined as those exhibiting a human plasma TTR binding stoichiometry >1.5) TTR kinetic stabilizers to the thyroid hormone receptor is shown in red font. Individual efficacy scores (as defined by eq 2) of TTR kinetic stabilizers are shown in green font, whereas average efficacy scores (defined by eq 1) are shown at the bottom of the columns (reflecting the average value in a column) and at the right side of the rows, reflecting the average value of the compounds in that row.

amyloidogenesis (7.2 μ M;⁵⁹ see below), herein we first set out to optimize the structure of stilbene-based TTR kinetic stabilizers using previously determined aryl-Z ring efficacy scores to guide this substructure combination strategy. Second, we used the substructure combination strategy to evaluate the highly ranked $-\text{CH}_2-\text{CH}_2-$ linker, readily synthesized by hydrogenation of the double bond of the stilbenes. Third, we used the substructure combination strategy to demonstrate that by further optimizing the aryl-X ring we could remove an off-target binding activity. The chemical purity of all compounds used in this study was $\geq 95\%$, Figures S1–S3.

Inhibition of Acid-Mediated WT-TTR Amyloid Formation by Candidate Kinetic Stabilizers. The efficacy with which stilbene and dihydrostilbene library members inhibit WT-TTR amyloidogenesis was evaluated using the previously established acid-mediated fibril formation assay.^{20,58–60} Briefly, each compound (7.2 μ M, the minimum concentration required to occupy both T₄ binding sites) was preincubated with a physiologically relevant concentration of WT-TTR (3.6 μ M) for 30 min, and TTR amyloidogenesis was initiated by adjusting the pH to 4.4. The extent of TTR fibril formation was quantified by measuring

turbidity, previously shown to be equivalent to thioflavin T quantification. At this pH, a 90% yield of TTR fibril formation is observed after a 72 h incubation period in the absence of a TTR kinetic stabilizer. TTR amyloidogenesis in the presence of a candidate kinetic stabilizer was expressed as a percentage relative to that exhibited by WT-TTR in the absence of inhibitor (assigned to be 100%). Potent TTR kinetic stabilizers allow <10% of WT-TTR fibril formation at a concentration of 7.2 μ M and <40% of WT-TTR fibril formation at a concentration equal to that of WT-TTR (3.6 μ M) (0% fibril formation = 100% inhibition).^{5,15,55,56,58–60,62,64–67,69–72} Of the 87 stilbene- and dihydrostilbene-based kinetic stabilizers synthesized and evaluated here, 80 are excellent amyloidogenesis inhibitors, allowing <10% of WT-TTR fibril formation at a concentration of 7.2 μ M (>90% inhibition, Figures 2–4, black font = % fibril formation). Compounds exhibiting more than 95% inhibition were reevaluated at a concentration equal to the TTR tetramer (3.6 μ M). At this concentration, the library of compounds allows between 15% and 30% of WT-TTR fibril formation (Figures S4–S6), demonstrating that the substructure combination strategy is capable of producing potent TTR kinetic stabilizers.

	F 16	Cl 17	CH ₃ 18	CF ₃ 19	OCH ₃ 20	OCHF ₂ 21	NO ₂ 22	NH ₂ 23	Average Efficacy Score
a	2% 1.41 0.79	2% 1.42 0.79	1% 1.49 0.82	2% 1.52 0.82	2% 1.73 0.89	3% 1.57 0.83	2% 1.62 0.86	1% 1.37 0.78	0.82
b	2% 1.63 0.86	1% 1.34 0.77	3% 1.50 0.81	1% 1.40 0.79	1% 1.64 0.87	1% 1.37 0.78		1% 1.53 0.84	0.82
c	2% 1.48 0.81	1% 1.46 0.81	1% 1.47 0.82		2% 1.35 0.75	1% 1.08 0.69		2% 1.57 0.84	0.77
d	1% 1.55 0.84	3% 1.61 0.84	2% 1.55 0.83		1% 1.57 0.85				0.84
e	2% 1.46 0.80		2% 1.43 0.83		1% 1.30 0.76				0.79
Average Efficacy Score	0.82	0.81	0.82	0.81	0.82	0.77		0.82	

Figure 3. Evaluation of the potency and selectivity of dihydrostilbene-based WT-TTR kinetic stabilizers. This figure is organized and defined strictly analogous to the descriptions in the legend to Figure 2.

X		Z = <i>m</i> -OCH ₃	<i>o</i> -(OCH ₃) ₂	<i>m</i> -NH ₂	<i>p</i> -NH ₂
OH		9b	9d	13b	13c
	% Fibril Formation	0%	0%	0%	1%
	Binding Stoichiometry	1.63	1.52	1.76	1.93
	% TH Receptor Binding	0%	0%	0%	0%
	Efficacy Score	0.88	0.84	0.92	0.97
NH ₂		24b	24c	24d	24e
	% Fibril Formation	1%	1%	1%	1%
	Binding Stoichiometry	0.69	1.47	1.26	1.33
	% TH Receptor Binding	1%	2%	3%	0%
	Efficacy Score	0.56	0.82	0.75	0.77

Figure 4. Effect of replacement of a hydroxyl group by an amino group in selected TTR kinetic stabilizers. Percent fibril formation (% F.F.) values (black font), plasma TTR binding stoichiometry (blue font), T₃ displacement from thyroid hormone receptor (red font), as well as individual efficacy scores (green font) are shown, precisely as defined in Figure 2, with the exception that average efficacy scores are not shown.

Binding Stoichiometry of Potent Kinetic Stabilizers to TTR in Human Blood Plasma. The 80 stilbene and dihydrostilbene kinetic stabilizers that allowed <10% of WT-TTR fibril formation *in vitro* were further evaluated for their ability to bind selectively to TTR in human blood plasma (3.6–5.4 μM) using the established *ex vivo* TTR plasma binding selectivity assay.⁷³ Briefly, the candidate kinetic stabilizer (10.8 μM) was incubated with human blood plasma at 37 °C for 24 h. Any unbound inhibitors, endogenous small molecules, or macromolecules that could bind to the resin used in the next step were removed by addition of quenched sepharose resin.⁷³ The TTR and TTR•(kinetic stabilizer)_n complexes in the plasma were immunocaptured using a sepharose-resin-conjugated anti-TTR antibody. After extensive washing, TTR and any TTR•small molecule complexes bound to the resin were dissociated by high pH treatment. The ratio of TTR monomer to bound candidate kinetic stabilizer was calculated from HPLC peak areas using standard curves.⁷³ The numbers in blue font in Figures 2–4 represent the average candidate kinetic stabilizer binding stoichiometry to TTR in human blood plasma, the maximum being 2, due to two thyroxine binding sites per TTR tetramer. Of the 80 potent (<10% fibril formation) TTR aggregation inhibitors evaluated, only three kinetic stabilizers display modest binding stoichiometry (<1 equivalent bound), whereas 77 inhibitors exhibit

(73) Purkey, H. E.; Dorrell, M. I.; Kelly, J. W. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, 98, 5566–71.

average binding stoichiometries exceeding 1 equivalent bound per tetramer. Notably, 37 of these display exceptional binding selectivity to plasma TTR, exhibiting >1.5 equivalents bound per TTR tetramer. It is reassuring that the substructure combination strategy yields stilbenes and dihydrostilbenes that generally exhibit very high individual efficacy scores (eq 2), reflecting desirable amyloid inhibition efficacy and plasma TTR binding selectivity (Figures 2–4, numbers in green font, 1 being a perfect kinetic stabilizer).

$$\text{individual efficacy score} = \frac{(100\% - \%F.F.) \times (1 + P.S.)}{300\%} \quad (2)$$

Average efficacy scores (eq 1) are also depicted in bold black font in Figures 2 and 3 in the bottom row and the rightmost column. In this calculation, we average % fibril formation (% F.F._{ave}) and plasma TTR binding stoichiometry (P.S._{ave}) values in each column where the substituent(s) is constant but the positioning on the aryl ring varies, and in each row where the substituent(s) vary but the positioning on the aryl ring is constant.

Evaluating TTR Kinetic Stabilizers for Thyroid Hormone Receptor Binding. Because the majority of the members of our stilbene and dihydrostilbene library are composed of the 3,5-dibromo-4-hydroxyphenyl thyroxine-like substructure, we were concerned about their binding selectivity to TTR over the thyroid hormone receptor. Thus, TTR kinetic stabilizers were evaluated for their ability to bind to the thyroid hormone receptor [analyses carried out by Cerep laboratories in Redmond, WA (see Experimental Section for details)]. The results are expressed as percent displacement of the control radioligand (¹²⁵I)-labeled triiodothyronine, [¹²⁵I]-T₃. Greater than 20% displacement of [¹²⁵I]-T₃ by candidate kinetic stabilizers indicates undesirable library members. Of the 41 TTR kinetic stabilizers evaluated, nearly one-half (11 stilbene analogues and 10 dihydrostilbene analogues) exhibit insignificant thyroid hormone receptor binding (<20%) (Figures 2–4, % values in red font). These compounds are promising lead TTR kinetic stabilizers. Given the rarity of thyroid hormone receptor binding in the previous study that identified the 3,5-dibromo-4-hydroxy substructure as optimal,⁵⁸ it was disappointing, but perhaps not shocking, that one-half of the stilbenes and dihydrostilbenes tested bound to thyroid hormone receptor.

Replacing the Phenolic Group in 3,5-Dibromo-4-hydroxyphenyl-Based Stilbenes. In a modest effort toward further aryl-X substructure optimization, we asked whether we could substitute the hydroxyl group in the context of a simple stilbene composed of one unsubstituted aryl ring (aryl-Z) and one ring bearing 3,5-dibromo-substituents and a variable 4-position substituent without losing potency and selectivity. We considered a variety of functional groups at the 4-position (Figure S7). The amino group was equivalent to the hydroxyl group in terms of potency, an encouraging result as anilines are functional groups in FDA-approved drugs. However, some anilines are carcinogenic in animals, and possibly in humans. Motivated by this result, four stilbenes with aniline-based aryl-X rings and substituted aryl-Z substituents were synthesized (Figure 4, compounds **24b–e**) to assess both potency and selectivity. Given the limited number of compounds that were synthesized and the diversity of Z-substituents, the potency of these compounds (Figure 4, % F.F. numbers in black font) was impressive, demonstrating the merit of further aryl-X optimization. Moreover, three of these compounds exhibit excellent TTR




Figure 5. The influence of kinetic stabilizer binding on the rate of TTR tetramer dissociation. WT-TTR (1.8 μM) tetramer dissociation time courses in 6 M urea without (■) and in the presence of putative kinetic stabilizers **9d**, **13c**, **20d**, **23c**, **24c**, and **24e** at a concentration of 3.6 μM (A) and 1.8 μM (B), evaluated by linking the slow tetramer dissociation process to rapid and irreversible monomer denaturation in 6 M urea, as measured by far-UV circular dichroism at 215–218 nm over a time course of 144 h.

binding selectivity in plasma (Figure 4, numbers in blue font). Notably, none of these compounds bind to the thyroid hormone receptor (Figure 4, percentage in red font), suggesting that further aryl-X optimization may be an effective strategy to reduce TTR kinetic stabilizer thyroid hormone receptor binding. This limited series exhibits impressive individual efficacy scores (Figure 4, numbers in green font). Moreover, as discussed in detail below, the distinct inner binding subsite preference of the 3,5-dibromo-4-aminophenyl substructure nicely complements the outer binding site preference of the 3,5-dibromo-4-hydroxyphenyl substructure discussed above, providing another substructure to include in future substructure combination strategies.

Demonstrating That Potent Amyloidogenesis Inhibitors Are Kinetic Stabilizers of WT-TTR. TTR fibril formation is rate limited by tetramer dissociation.^{5,20–26} Thus, the imposition of kinetic stabilization on TTR by small molecule binding to the TTR tetramer can be measured by the rate of tetramer dissociation, which is assessed by linking the slow tetramer dissociation step to rapid monomer unfolding, easily quantified using far-UV circular dichroism (CD) or fluorescence spectroscopy.^{5,11,54} To demonstrate kinetic stabilization of TTR, we preincubated WT-TTR (1.8 μM) with candidate kinetic stabilizers (1.8 or 3.6 μM) for 30 min. Dissociation was then accelerated and made measurable on a convenient laboratory time scale by adding urea to a final concentration of 6 M. The rate and extent of dissociation was monitored by the thermodynamically linked monomer unfolding of WT-TTR at 25 °C, followed by far-UV CD over 144 h. All candidate kinetic stabilizers at a concentration of 3.6 μM dramatically slowed dissociation, allowing less than 15% of the TTR to dissociate (Figure 5A). Tetramer

dissociation was also clearly slowed at a kinetic stabilizer concentration of 1.8 μM , equal to that of the TTR tetramer, allowing 20–33% tetramer dissociation, indicating that the binding of one small molecule to one of the two T_4 binding sites is sufficient to stabilize the ground state over the dissociative transition state, imposing kinetic stabilization on the entire TTR tetramer (Figure 5B).

Inhibition of WT- and V30M-TTR-Induced Cytotoxicity by Potent Kinetic Stabilizers. Previous studies demonstrate that treatment of cell lines derived from tissues that are targets of TTR deposition with recombinant WT-TTR or V30M-TTR homotetramers results in proteotoxicity.^{19,74,75} Moreover, these studies establish that TTR cytotoxicity can be inhibited by small molecules that kinetically stabilize TTR against dissociation.^{19,74} Previous experiments conclude that partially folded monomers and/or oligomers resulting from TTR dissociation and misassembly are the major cytotoxic species in cell culture.¹⁹ Resveratrol (**1**) is known to bind to and kinetically stabilize WT- and V30M-TTR and reduce their cytotoxicity, and therefore was used as the positive control. WT-TTR and V30M-TTR were preincubated without and with equimolar amounts of candidate kinetic stabilizers or **1** at 4 °C for 18 h. The human neuroblastoma IMR-32 cells were treated with these solutions (8 μM final concentration of TTR and compounds) for 24 h at 37 °C, after which cell viability was assessed by the resazurin reduction assay.⁷⁶ Viable cells reduce the substrate resazurin to resorufin, a fluorescent compound, which was monitored by fluorescence emission at 590 nm. The results are expressed as the percentage of fluorescence generated by viable cells treated with vehicle only (100% viable). Cells treated with cytotoxic TTR in the absence of kinetic stabilizers exhibit 45–65% viability. All of the kinetic stabilizers tested nearly completely inhibit WT-TTR and V30M-TTR-induced cytotoxicity at a final concentration equimolar to that of TTR (Figure 6A). Importantly, none of the compounds evaluated were cytotoxic to IMR-32 cells in the absence of TTR (>80% cell viability (Figure 6B)). Thus, the substructure combination strategy affords compounds that protect against TTR proteotoxicity.

Crystallographic Analysis of WT-TTR•(Kinetic Stabilizer)₂ Complexes. Crystal structures of WT-TTR in complex with **3d**, **13c**, **17d**, and **24c–e** were determined to 1.70, 1.40, 1.40, 1.32, 1.40, and 1.48 Å resolutions, respectively (see Table 1 for data collection and refinement statistics). In all six structures, the electron density was clear and allowed unambiguous placement of the ligand (unbiased $2F_o - F_c$ electron density maps contoured at 3σ shown in Figure S8). As anticipated, the 3,5-dibromo-4-hydroxyphenyl rings of stilbene **3d** and dihydrostilbene **17d** contribute to binding by their placement in the complementary T_4 outer binding subsite,^{58,59} positioning the bromides in HBPs 1 and 1'. The phenolate anion of **3d** and **17d** appears to engage in a salt bridge interaction with the ϵ -ammonium group of Lys15/15' (Figure 7A and C). The 2,6-dichlorophenyl ring in **3d** and **17d** occupies the inner binding subsite, directing the chloride atoms into HBPs 3 and 3', stacking the face of the aryl ring between the two symmetry-related Leu110 residues (Figure 7A and C). In the case of




Figure 6. (A) Demonstration that kinetic stabilizers of WT-TTR and V30M-TTR can prevent cytotoxicity associated with the process of TTR amyloidogenesis. IMR-32 human neuroblastoma cells were treated with WT-TTR (8 μM , white bar) or V30M-TTR (8 μM , gray bar), exhibiting cytotoxicity that is prevented by preincubating WT-TTR (white bars) or V30M-TTR (gray bars) with the stilbene and dihydrostilbene-based kinetic stabilizers or resveratrol (**1**) (a kinetic stabilizer previously shown to be effective) included as a positive control (8 μM each). Cell viability was measured after 24 h by the resazurin reduction assay, and all of the experimental conditions were compared to cells treated with vehicle only (100% cell viability). (B) Cytotoxicity of selected compounds (8 μM) to the human neuroblastoma cell line IMR-32. Columns represent the average values of two independently performed experiments (six experimental replicates). The error bars represent standard error.

stilbene **13c**, composed of a 3,5-dibromo-4-hydroxyphenyl aryl-X ring and a *p*-amino aryl-Z ring, a mixture of two binding orientations is observed in the electron density. The 3,5-dibromo-4-hydroxyphenyl ring occupies the T_4 outer binding subsite ~90% of the time for reasons described above, orientating the *p*-amino group from the aryl-Z ring to make bridging hydrogen bonds with Ser117/117' side chains (Figure 7B). In the minor binding orientation, the 3,5-dibromo-4-hydroxyphenyl ring of **13c** occupies the inner binding subsite and the phenol/phenolate makes hydrogen bonds with Ser117/117' side chains, while the bromides occupy HBPs 3 and 3' (Figure 7B).

In stilbenes **24c–e**, the 3,5-dibromo-4-aminophenyl substructure was placed in the inner binding subsite in all cases. This binding orientation appears to be stabilized by bridging hydrogen bonds between the amino substituent and the Ser117/117' hydroxyl side chains and by simultaneous placement of the bromides into HBPs 3 and 3' (Figure 7D–F). The *p*- or *m*-amino substituent on the other ring in **24d** and **24e** does not appear to interact with TTR, and thus the aryl-Z ring can be further optimized by the substructure combination strategy. The dimethoxyphenyl groups on **24c** were able to interact with HBPs 1 and 1' (Figure 7D).

In all six structures, the *trans* $-\text{CH}=\text{CH}-$ or $-\text{CH}_2-\text{CH}_2-$ linker occupies the hydrophobic pocket created by residues Leu17/17', Ala108/108', Leu110/110', and Val121/121'. These linkers afford the aryl rings some degree of rotational freedom

(74) Reixach, N.; Adamski-Werner, S. L.; Kelly, J. W.; Koziol, J.; Buxbaum, J. N. *Biochem. Biophys. Res. Commun.* **2006**, *348*, 889–97.

(75) Sörgjerd, K.; Klingstedt, T.; Lindgren, M.; Kågedal, K.; Hammarström, P. *Biochem. Biophys. Res. Commun.* **2008**, *377*, 1072–8.

(76) O'Brien, J.; Wilson, I.; Orton, T.; Pognan, F. *Eur. J. Biochem.* **2002**, *267*, 5421–6.

Table 1. Crystallographic Data and Refinement Statistics

	WT-TTR·3d	WT-TTR·13c	WT-TTR·17d	WT-TTR·24c	WT-TTR·24d	WT-TTR·24e
Data Collection						
beamline	SSRL 9-2	APS GM/CA-CAT 23-IDB	SSRL 11-1	SSRL 11-1	SSRL 11-1	SSRL 11-1
wavelength (Å)	0.9194	1.0333	0.9797	0.9797	0.9797	0.9797
resolution (Å)	1.70 (1.70–1.76) ^a	1.40 (1.40–1.45)	1.40 (1.40–1.45)	1.31 (1.31–1.36)	1.40 (1.40–1.45)	1.48 (1.48–1.53)
space group	<i>P</i> ₂ ₁ ₂ ₁ ₂	<i>P</i> ₂ ₁ ₂ ₁ ₂	<i>P</i> ₂ ₁ ₂ ₁ ₂	<i>P</i> ₂ ₁ ₂ ₁ ₂	<i>P</i> ₂ ₁ ₂ ₁ ₂	<i>P</i> ₂ ₁ ₂ ₁ ₂
<i>a</i> , <i>b</i> , <i>c</i> (Å)	42.92, 85.0, 64.50	42.26, 84.79, 63.24	42.50, 85.11, 63.32	42.8, 85.38, 64.39	42.7, 85.29, 64.2	42.78, 85.16, 64.16
no. of molecules in the au	2	2	2	2	2	2
no. of observations	376642 (30797) ^a	322489 (31176)	165495 (16232)	268463 (20385)	220973 (18236)	192765 (18569)
no. of unique reflections	26903 (2588)	44988 (4391)	45971 (4509)	56323 (4972)	46374 (4342)	39462 (3951)
redundancy	14.0 (11.9) ^a	7.2 (7.1)	3.6 (3.6)	4.8 (4.1)	4.8 (4.2)	4.9 (4.7)
completeness (%)	99.5 (97.0) ^a	98.8 (98.0)	99.7 (99.6)	97.6 (87.3)	98.2 (93.6)	97.7 (99.4)
<i>R</i> _{sym} (%) ^b	5.7 (69.5) ^b	5.0 (57.4)	4.0 (45.2)	3.1 (46.1)	2.9 (48.3)	3.4 (52.3)
average <i>I</i> / <i>σ</i>	34.6 (7.3) ^a	28.3 (3.6)	26.1 (3.1)	37.5 (2.8)	45.5 (2.2)	36.5 (3.3)
Refinement Statistics						
resolution (Å)	1.70–64.55	1.40–84.82	1.40–63.37	1.31–85.44	1.40–85.13	1.47–85.13
no. of reflections (working set)	25229 (1781) ^a	42702 (2843)	43555 (3170)	53423 (3720)	44010 (2940)	37452 (2478)
no. of reflections (test set)	1333 (93) ^a	2257 (154)	2332 (177)	2869 (203)	2340 (142)	1981 (121)
<i>R</i> _{cryst} (%) ^c	16.9 (17.9) ^{a,c}	16.3 (21.4)	16.5 (19.8)	16.7 (28.8)	16.8 (25.3)	16.7 (23.4)
<i>R</i> _{free} (%) ^d	21.6 (26.4) ^{a,d}	19.0 (27.0)	19.7 (25.8)	19.7 (30.7)	19.0 (32.7)	20.0 (26.7)
Average <i>B</i> -Values						
TTR	22.3	17.1	14.7	18.6	20.5	19.6
ligand	45.3	20.4 <i>R</i> , 27.2 <i>F</i>	15.9	18.4	28.6	26.4
Wilson <i>B</i> -value	23.6	19.0	17.1	18.2	22.0	21.7
Ramachandran Plot						
most favored (%)	92.1	93.0	91.1	93.0	93.5	93.5
additionally allowed (%)	7.9	7.0	8.9	7.0	6.5	6.5
generously allowed (%)	0	0	0	0	0	0
disallowed (%)	0	0	0	0	0	0
RMS Deviations						
bond lengths (Å)	0.019	0.018	0.018	0.016	0.018	0.018
angles (deg)	1.81	1.71	1.74	1.78	1.64	1.61

^a Numbers in parentheses are for the highest resolution shell of data. ^b $R_{\text{sym}} = \sum_{hkl} |I - \langle I \rangle| / \sum_{hkl} I$. ^c $R_{\text{cryst}} = \sum_{hkl} |F_o - F_c| / \sum_{hkl} F_o$. ^d R_{free} is the same as R_{cryst} , but for 5% of data excluded from the refinement. *F/R* = forward or reverse conformations of the ligand.

enabling optimal placement of the two substituted rings into HBPs 1, 1' and 3, 3'.

Discussion

A substructure combination strategy was employed herein, based on previous aryl-X, linker-Y, and aryl-Z substructure rankings,^{58–60} to guide the synthesis of a library of stilbenes and dihydrostilbenes. This effort afforded a high fraction of potent and highly selective TTR kinetic stabilizers that rescue cells from the cytotoxic effects of TTR amyloidogenesis thought to cause the human amyloidoses, without exhibiting cytotoxicity themselves. The stilbene and dihydrostilbene libraries depicted in Figures 2 and 3 were made up of combinations of substructural components exhibiting high average efficacy scores in the aforementioned three-part study.^{58–60} Even though more of the 3,5-dibromo-4-hydroxyphenyl-based stilbenes and dihydrostilbenes afforded thyroid hormone binding capacity than the previous substructure optimization studies would have predicted,^{58–60} a further aryl-X ring and/or aryl-Z substructure optimization strategy may produce potent and selective compounds lacking this property.

We calculated individual efficacy scores according to eq 2 for each compound synthesized and evaluated in this study, Figures 2–4. The individual efficacy scores displayed in Figure 2 reveal that the substructure combination strategy was very effective, in that 96% of the stilbenes examined exhibit an efficacy score >0.57 out of a maximum of 1. The efficacy score of 0.57 was chosen as a benchmark, because this is the efficacy score of the compound that ameliorated familial amyloid polyneuropathy in a placebo-controlled clinical trial (www.foldrx.com). Compounds exhibiting >10% fibril formation at

a concentration twice that of TTR, for which plasma binding stoichiometry was not assessed, were assumed to have an efficacy score <0.57.

The individual efficacy scores displayed in Figure 3 reveal that the linker substructure combination strategy was also very effective. All of the dihydrostilbenes examined exhibit an efficacy score >0.57 out of a maximum of 1. We did not prepare quite as many dihydrostilbenes as we did stilbenes, and it could be argued that we hydrogenated the stilbenes exhibiting high efficacy scores; hence it is probably not appropriate to conclude that dihydrostilbenes are superior to stilbenes. Nonetheless, we sampled quite a range of substituents and substitution patterns in both libraries, indicating that the substructure combination strategy was quite effective in the context of both stilbenes and dihydrostilbenes.

Surprisingly, only 30% of the promising stilbene compounds evaluated displaced <20% of T₃ from the thyroid hormone receptor. This was unexpected because the compounds resulting from the individual substructure optimization studies displayed much less T₃ displacement.^{58–60} However, the problem of T₃ displacement seems to be easily remedied by a linker replacement affected by simply hydrogenating the thyroid receptor binding stilbenes. More than 76% of the promising dihydrostilbenes evaluated displaced <20% of T₃ from the thyroid hormone receptor. Another means of correcting the T₃ displacement problem could be to perform additional aryl-X substructure optimization and combination strategies.

The structural data presented herein provide further evidence for the strong preference of the 3,5-dibromo-4-hydroxyphenyl ring to occupy the outer binding subsite of TTR in the context of stilbenes and dihydrostilbenes (Figure 7A–C). In stark




Figure 7. Crystal structures of homotetrameric WT-TTR in complex with inhibitors **3d**, **13c**, **17d**, **24c**, **24d**, and **24e**. Ribbon diagram depiction of a close-up view of one of the two identical T₄ binding sites (see Figure 1A). A “Connolly” analytical molecular surface was applied to residues within 8 Å of ligand in the T₄ binding pocket (green = hydrophobic, purple = polar). Polar residues K15 and S117/117' are shown with bonds depicted where interactions are observed. In the case of stilbene **13c**, a mixture of two binding orientations is observed. The 3,5-dibromo-4-hydroxyphenyl ring occupies the thyroxine outer binding subsite ~90% of the time (see Results for a more complete description and explanation). This figure was generated using the program MOE (2006.08), Chemical Computing Group, Montreal, Canada.

contrast, the structural data reveal that the 3,5-dibromo-4-aminophenyl ring strongly prefers to occupy the inner binding subsite in the context of stilbenes (Figure 7D–F). On the basis of this result, we predict that stilbenes and dihydrostilbenes composed of one 3,5-dibromo-4-hydroxyphenyl ring, which prefers to bind in the outer thyroxine binding subsite, and one 3,5-dibromo-4-aminophenyl ring, which prefers to bind to the inner thyroxine binding subsite, will exhibit high individual efficacy scores. The substructure combination strategy used herein to generate potent and selective stilbene and dihydrostilbene TTR kinetic stabilizers could be successfully applied to generate potent and selective 2-aryl benzoxazole-based TTR kinetic stabilizers as well. Not only is the heteroaromatic ring of a benzoxazole a highly ranked linker,⁵⁹ but previous studies that were much more limited in scope demonstrate that benzoxazoles are excellent TTR kinetic stabilizers.⁶²

The kinetic studies carried out herein demonstrate that selective binding of small molecules to the native tetrameric state of TTR drastically slows the rate of tetramer dissociation, by increasing the energy barrier for dissociation. We also showed that the kinetic stabilization of TTR imposed by the binding of these compounds precludes TTR-mediated cytotoxicity using a recently introduced cytotoxicity assay, by preventing tetramer dissociation that leads to monomers and oligomers previously shown to be the cytotoxic species. Because amyloidogenesis-linked neurotoxicity and cardiotoxicity is thought to cause FAP and SSA, respectively, we envision that this assay, not utilized in the prior substructure optimization studies, will

be useful for predicting compounds that will show efficacy in human patients.

Conclusions

We have successfully utilized the data generated in three previous substructure optimization papers to identify potent and selective stilbene and dihydrostilbene kinetic stabilizers using a substructure combination strategy. We also showed that this strategy is useful for eliminating off-target activities, such as thyroid hormone receptor binding. Notably, the majority of the kinetic stabilizers emerging from the substructure combination strategy exhibit high individual efficacy scores and prevent TTR amyloidogenesis-associated cytotoxicity in a cell culture model that we believe is predictive for kinetic stabilizer efficacy in the human TTR amyloidoses. There is reason to be optimistic that a subset of the potent and selective stilbene- and dihydrostilbene-based TTR kinetic stabilizers produced in this study will exhibit the appropriate pharmacokinetic and pharmacodynamic properties to motivate their further development.

Experimental Section

Wild Type Transthyretin Fibril Formation Assay. WT-TTR was expressed and purified from an *E. coli* expression system as described previously.⁷⁷ To assess fibril formation, a test compound (5 μL of a 1.44 mM solution in DMSO) was added to 495 μL of

(77) Lashuel, H. A.; Wurth, C.; Woo, L.; Kelly, J. W. *Biochemistry* **1999**, *38*, 13560–73.

a solution of TTR (0.4 mg/mL) in 10 mM phosphate, 100 mM KCl, and 1 mM EDTA (pH 7.0) in a disposable cuvette. The mixture was vortexed and incubated at room temperature for 30 min. An acidic buffer solution (500 μ L of 100 mM acetate, 100 mM KCl, 1 mM EDTA, pH 4.2) was then added to decrease the pH of assay solution to 4.4. The cuvettes were incubated at 37 $^{\circ}$ C for 72 h without agitation. After the solution was vortexed to evenly distribute any precipitate, the turbidity of the solution at 400 nm was measured using a Hewlett-Packard model 8453 UV-vis spectrophotometer.

Evaluating the Binding Stoichiometry of Candidate Kinetic Stabilizers to TTR in Human Blood Plasma. The plasma TTR binding selectivity assay that evaluates the binding stoichiometry of a test compound to TTR in human blood plasma has been previously described⁷³ and is used with minor modifications. Briefly, to a 1 mL sample of human blood plasma in a 2 mL Eppendorf tube was added a test compound (7.5 μ L of a 1.44 mM solution in DMSO), and then the plasma solution was incubated at 37 $^{\circ}$ C for 24 h on a rocker plate (30 rpm). A 1:1 (v/v) slurry of unfunctionalized sepharose resin in TSA (10 mM Tris, 140 mM NaCl, pH 8.0) buffer was added, and the solution was incubated for 1 h at 4 $^{\circ}$ C on a rocker plate (18 rpm). The solution was then centrifuged, and the supernatant was divided into two 400 μ L aliquots, which were added to 200 μ L of 1:1 (v/v) slurry of anti-TTR antibody conjugated sepharose resin in TSA. The solution was gently rocked (18 rpm) at 4 $^{\circ}$ C for 20 min, then centrifuged, and the supernatant removed. The resin was washed three times by shaking for 1 min with 1 mL of TSA containing 0.05% saponin and then twice more with 1 mL of TSA. After centrifugation to remove the supernatant, 155 μ L of triethylamine (100 mM, pH 11.5) was added to the sepharose resin to dissociate the TTR and bound test compound from the resin, and the suspension was vortexed for 1 min. After centrifugation, 144 μ L of the supernatant containing the test compound and TTR was neutralized by addition of 0.84 μ L of glacial acetic acid before HPLC analysis. The supernatant was analyzed by reverse phase HPLC, as described previously,⁷³ on a Waters 600 E multisolvent delivery system, using a Waters 486 tunable absorbance detector, a 717 autosampler, and a ThermoHypersil Keystone Betabasic-18 column (150 $\text{\AA}$ pore size, 3 μ m particle size). The "A" mobile phase comprises 0.1% TFA in 94.9% H₂O + 5% CH₃CN, and the "B" mobile phase is made up of 0.1% TFA in 94.9% CH₃CN + 5% H₂O. Linear gradients were run from 100:0 A:B to 0:100 A:B for 9 min.

Binding of Potent TTR Amyloidogenesis Inhibitors to the Thyroid Hormone Receptor. The potential binding of TTR kinetic stabilizers to the thyroid hormone receptor was evaluated by Cerep laboratories in Redmond, WA, using the following experimental protocol. Membrane homogenates of liver (100 μ g of total protein) are incubated for 18 h at 4 $^{\circ}$ C with 0.1 nM [¹²⁵I]T₃ in the absence or presence of a TTR kinetic stabilizer in buffer (20 mM Tris-HCl, pH 7.6, 50 mM NaCl, 2 mM EDTA, 10% glycerol, and 5 mM β -mercaptoethanol). Nonspecific binding is corrected for in the presence of 1 μ M T₃. Following the incubation period, the samples are filtered rapidly under vacuum through glass fiber filters (GF/B, Packard) and rinsed several times with an ice-cold buffer containing 50 mM Tris-HCl and 150 mM NaCl (pH 7.4), employing a 96-sample cell harvester (Unifilter, Packard). The filters are dried, then counted for radioactivity in a scintillation counter (Topcount, Packard) using a scintillation cocktail (Microscint 0, Packard).

Urea-Induced Dissociation Kinetics Study. Slow TTR tetramer dissociation is not detectable by far-UV circular dichroism (CD) spectroscopy; however, dissociation is linked to rapid ($\sim$ 500 000 $\times$ faster) monomer unfolding under denaturing conditions, which is easily detectable by far-UV CD spectroscopy. Test compounds (5 and 10 mM in DMSO) were diluted 10-fold in EtOH to give 0.5 and 1 mM stock solutions. Such stocks (7.2 μ L) were added to 200 μ L of TTR (18 μ M in 10 mM sodium phosphate buffer, 100 mM KCl, 1 mM EDTA (pH 7.0)) in 2 mL Eppendorf tubes. These mixtures were briefly vortexed and incubated for 30 min at 25 $^{\circ}$ C.

TTR/test compounds (100 μ L) were added to 900 μ L of a 6.67 M urea solution in 10 mM sodium phosphate buffer, 100 mM KCl, and 1 mM EDTA (pH 7.0) to give a final concentration of 1.8 μ M for TTR and final concentrations of test compound of 1.8 μ M (1X) and 3.6 μ M (2X), respectively. The mixtures were vortexed and incubated in the dark at 25 $^{\circ}$ C without agitation. CD spectra at a final urea concentration of 6 M were measured at 215–218 nm (0.5 nm steps and five times scan) after 0, 5, 10, 25, 48, 72, 96, 120, and 144 h of incubation.

IMR-32 Cell-Based Assay. Cells. The IMR-32 human neuroblastoma cell line was maintained in Opti-MEM (cell culture medium, Invitrogen), supplemented with 5% fetal bovine serum, 1 mM Hepes buffer, 2 mM L-glutamine, 100 units/mL penicillin, 100 μ g/mL streptomycin, and 0.05 mg/mL CaCl₂ (complete cell medium). The 2–3-day-old cultures (70% confluent) were used for the cytotoxicity experiments.

Recombinant WT-TTR and V30M-TTR purified at 4 $^{\circ}$ C and capable of amyloidogenesis were used as cytotoxic insults to IMR-32 cells. The proteins were buffer exchanged in Opti-MEM at 10 $^{\circ}$ C using a Centriprep device (10 kDa MWCO, Millipore).

Stocks of the TTR kinetic stabilizers were prepared at 1 mM in 0.5% DMSO/Opti-MEM and stored at -20° C. For the experiments, test compounds (32 μ M in Opti-MEM) were mixed 1:1 with filtered-sterilized TTR (32 μ M in Opti-MEM) or with Opti-MEM only, vortexed, and incubated for 18 h at 4 $^{\circ}$ C. TTR (16 μ M) alone and Opti-MEM alone containing the same amount of DMSO used above were prepared in parallel and incubated under the same conditions.

IMR-32 cells were seeded in black wall, clear bottom, 96-well tissue culture plates (Costar) at a density of 6000 cells/well in complete cell medium and incubated overnight at 37 $^{\circ}$ C. The incubated TTR/test compound samples, TTR and Opti-MEM, were diluted 1:1 with freshly prepared Opti-MEM supplemented with 0.8 mg/mL bovine serum albumin, 2 mM Hepes buffer, 4 mM L-glutamine, 200 units/mL penicillin, 200 μ g/mL streptomycin, and 0.1 mg/mL CaCl₂. The medium from the cells was then removed and replaced immediately by the TTR/test compound mixtures, TTR or Opti-MEM. The 96-well plates were spun at 2000g for 30 min at 4 $^{\circ}$ C to allow the IMR-32 cells to reattach to the bottom of the wells. The cells were then incubated 24 h at 37 $^{\circ}$ C, after which cell viability was measured. The final concentration of both TTR and test compound was 8 μ M.

Cell Viability Assay. The viability of the cells treated with TTR or TTR/test compound mixtures was evaluated by resazurin reduction assay. Briefly, 10 μ L/well of resazurin (500 μ M in PBS) was added to each well and incubated for 2 h at 37 $^{\circ}$ C. Viable cells reduce resazurin to the highly fluorescent resorufin dye, which is quantitated in a multiwell plate reader (Exc/Em 530/590 nm, Tecan Safire2, Austria). Cell viability was calculated as percentage of fluorescence relative to cells treated with vehicle only (100% viability) after subtraction of blank fluorescence (wells without cells). All of the experimental conditions were performed at least in triplicate. Averages and standard error corresponding to two independently performed experiments were calculated using Graph-Prism (San Diego, CA).

Crystallization and Structure Determination of the WT-TTR/Ligand Complexes. The TTR protein was concentrated to 4 mg/mL in 10 mM sodium phosphate buffer and 100 mM KCl (pH 7.6) and cocrystallized at room temperature with a 5 molar excess of each ligand using the vapor-diffusion sitting drop method. All crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were cryo-protected with 10% v/v glycerol. Data for **13c** were collected at beamline GM/CA-CAT 23-IDB at the Advanced Photon Source (APS) at a wavelength of 1.0333 $\text{\AA}$. Data for **3d** were collected at beamline 9-2 and data for **17d** and **24c–e** at 11-1 at the Stanford Synchrotron Radiation Lightsource (SSRL) at wavelengths of 0.9194 and 0.9795 $\text{\AA}$, respectively. All diffraction data were indexed, integrated, and

scaled using HKL2000⁷⁸ in space group $P2_12_12$ with two subunits observed per asymmetric unit. The structure was determined by molecular replacement using the model coordinates of 2FBR⁷² in the program Phaser.⁷⁹ Further model building and refinement were completed using Refmac.⁸⁰ Hydrogens were added during refinement, and anisotropic B -values were calculated. Final models were validated using the JCSG quality control server incorporating Molprobit,⁸¹ ADIT (<http://rcsb-deposit.rutgers.edu/validate>) WHATIF,⁸² Resolve,⁸³ and Procheck.⁸⁴ Data collection and refinement statistics are displayed in Table 1.

Protein Data Bank Accession Code. Atomic coordinates and structure factors have been deposited in the Protein Data Bank and are available under accession codes 3IMR (WT-TTR in complex with **3d**), 3IMT (WT-TTR in complex with **13c**), 3IMS (WT-TTR in complex with **17d**), 3IMW (WT-TTR in complex with **24c**), 3IMU (WT-TTR in complex with **24d**), and 3IMV (WT-TTR in complex with **24e**).

Acknowledgment. We thank the NIH (DK46335 to J.W.K. and CA58896 and AI42266 to I.A.W.), the American Heart Association (0865061F to N.R.), as well as the Skaggs Institute for Chemical Biology and the Lita Annenberg Hazen Foundation for financial support. Technical support from Mike Saure and Gina Dendle is also greatly appreciated. We thank the General Clinical Research Center of the Scripps Research Institute for providing human blood.

(78) Otwinowski, Z.; Minor, W. *Methods Enzymol.* **1997**, 276, 307–26.

(79) Storoni, L. C.; McCoy, A. J.; Read, R. J. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2004**, 60, 432–8.

(80) Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **1997**, 53, 240–55.

(81) Lovell, S. C.; Davis, I. W.; Arendall, W. B., III; de Bakker, P. I.; Word, J. M.; Prisant, M. G.; Richardson, J. S.; Richardson, D. C. *Proteins* **2003**, 50, 437–50.

(82) Vriend, G. *J. Mol. Graphics* **1990**, 8, 52–6.

(83) Terwilliger, T. C. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2003**, 59, 38–44.

(84) Laskowski, R.; MacArthur, M.; Moss, D.; Thornton, J. *J. Appl. Crystallogr.* **1993**, 26, 283–91.

X-ray diffraction data for **13c** were collected at GM/CA-CAT 23-IDB beamline at the Advanced Photon Source, Argonne National Laboratory. Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Office of Basic Energy Sciences, under Contract No. W-31-109-Eng-38. X-ray diffraction data collection for **3d**, **17d**, and **24c–e** was carried out at the Stanford Synchrotron Radiation Laboratory, a national user facility operated by Stanford University on behalf of the U.S. Department of Energy, Office of Basic Energy Sciences. The SSRL Structural Molecular Biology Program is supported by the Department of Energy, Office of Biological and Environmental Research, and by the National Institutes of Health, National Center for Research Resources, Biomedical Technology Program, and the National Institute of General Medical Sciences. We would also like to acknowledge Drs. Stanfield, Dai, Yoon, Xu, and Ekiert for assisting with X-ray data collection.

Note Added after ASAP Publication. Due to a production error a typographical correction has been made to indicate "...87 stilbene- and dihydrostilbene-based kinetic stabilizers..." in the section entitled Inhibition of Acid-Mediated WT-TTR Amyloid Formation by Candidate Kinetic Stabilizers; the correct version publish ASAP on January 6, 2010.

Supporting Information Available: Detailed synthesis, characterization, and purities of stilbenes and dihydrostilbenes, efficacy of stilbenes and dihydrostilbenes at a concentration of 3.6 μ M, evaluation of a variety of related functional groups to replace the hydroxyl group, unbiased $2F_o - F_c$ electron density maps for the ligands in the WT-TTR•(kinetic stabilizer)₂ complexes, and cytotoxicity of selected kinetic stabilizers to the IMR-32 cell line. This material is available free of charge via the Internet at <http://pubs.acs.org>.

JA908562Q